{"DataElement":{"publicId":"2759871","version":"1","preferredName":"Hormone Therapy Dutasteride Finasteride Prior Administered Last Date","preferredDefinition":"the last date of treatment of dutasteride, a synthetic 4-azasteroid compound that competitively and specificly inhibits both 5-alpha-reductase 1 and 2 isoenzymes that convert testosterone to dihydrotestosterone, or finasteride, a synthetic azasteroid compound, administered as a prior hormone therapy.","longName":"HTX_DUT_FIN_P_A_L_DT","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2759867","version":"1","preferredName":"Hormone Therapy Dutasteride Finasteride Prior Administered","preferredDefinition":"information related to dutasteride, a synthetic 4-azasteroid compound that competitively and specificly inhibits both 5-alpha-reductase 1 and 2 isoenzymes that convert testosterone to dihydrotestosterone, or finasteride, a synthetic azasteroid compound, administered as a prior hormone therapy.","longName":"HORM_DUT_FIN_P_ADMIN","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2433915","version":"1","preferredName":"Hormone Therapy","preferredDefinition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level. The treatment may include administration of hormones or hormone analogs to the patient, or decreasing the level of hormones in the body by using hormone antagonists, or hormone ablation therapy. The concept covers but not limited to: intermittent or permanent hormone suppression or ablation in treatment of hormone-dependent tumors, hormone replacement therapy of any kind, hormonal component of gender reassignment therapy, hormonal contraception, surgical and radiation castration.","longName":"C15445","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hormone Therapy","conceptCode":"C15445","definition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"06674CCB-CDA8-04A9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-28","modifiedBy":"ONEDATA","dateModified":"2005-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2759865","version":"1","preferredName":"Dutasteride Finasteride Prior Administered","preferredDefinition":"A synthetic 4-azasteroid compound. Dutasteride competitively and specificly inhibits both 5-alpha-reductase 1 and 2 isoenzymes that convert testosterone to dihydrotestosterone. The type 2 isoenzyme is primarily active in the reproductive tissues, while the type 1 isoenzyme is also responsible for conversion of testosterone in the skin and liver. Inhibition of 5-alpha reductase leads to a reduction of dihydrotestosterone formation and subsequently prevents the enlargement of the prostate gland. Dutasteride is used in the treatment of benign prostatic hyperplasia.:A synthetic azasteroid compound.  Finasteride binds to and inhibits 5-alpha-reductase, thereby interfering with the enzymatic conversion of testosterone to 5-dihydrotestosterone, ultimately interfering with prostate growth. (NCI):Earlier in time or order.:Given.","longName":"C47503:C1099:C25629:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dutasteride","conceptCode":"C47503","definition":"A synthetic 4-azasteroid compound. Dutasteride competitively and specifically binds to isoenzymes 1 and 2 of 5 alpha-reductase, forming stable enzyme complexes and inhibiting the conversion of testosterone to 5 alpha-dihydrotestosterone (DHT); the reduction in DHT activity may mitigate or prevent enlargement of the prostate gland. The type 2 5 alpha-reductase isoenzyme is primarily active in the reproductive tissues, while the type 1 isoenzyme is also active in skin and the liver.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Finasteride","conceptCode":"C1099","definition":"A synthetic 4-azasteroid compound. Finasteride competitively binds to and inhibits steroid type II 5-alpha-reductase in the prostate gland, liver, and skin, thereby interfering with the enzymatic conversion of testosterone to 5-dihydrotestosterone (DHT) and reducing serum DHT levels. The reduction in serum DHT levels results in diminished stimulation of androgen receptors in the nuclei of prostate cells and, so, diminished prostate cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FCCB826-222B-6B3D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-06-16","endDate":null,"createdBy":"ALAIS","dateCreated":"2008-06-16","modifiedBy":"ONEDATA","dateModified":"2008-06-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FCCB826-223C-6B3D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-06-16","endDate":null,"createdBy":"ALAIS","dateCreated":"2008-06-16","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2192181","version":"1","preferredName":"Last Date","preferredDefinition":"the last date of an evaluation, assessment, or treatment.","longName":"LAST_DT","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"DATE","minLength":null,"maxLength":"8","minValue":null,"maxValue":null,"decimalPlace":null,"format":"mm/dd/yyyy","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008561","version":"1","preferredName":"Occurrences","preferredDefinition":"dates, times, and durations.","longName":"OCURS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B53BD1AB-090B-398B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-01-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2208025","version":"1","preferredName":"Last Date","preferredDefinition":"Coming after all others in time or space or degree or being the only one remaining.:a particular day specified as the time something has, or will, happen.","longName":"C25551:C25164","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Last","conceptCode":"C25551","definition":"Coming after all others in time or space or degree or being the only one remaining.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Date","conceptCode":"C25164","definition":"The particular day, month and year an event has happened or will happen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-3957-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E90113A5-47AF-142F-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-11-16","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-11-16","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811910","version":"1","longName":"Prostate","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811953","version":"1","longName":"Disease Description","context":"CTEP"},{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Last date of finasteride or d","type":"Preferred Question Text","description":"Last date of finasteride or dutasteride treatment","url":null,"context":"CTEP"}],"origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"4FCCE14D-909C-0198-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-06-16","endDate":null,"createdBy":"ALAIS","dateCreated":"2008-06-16","modifiedBy":"CAMPBELB","dateModified":"2008-06-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}